Rexulti Net Sales in the U.S. for 2023
In 2023, U.S. net sales for Rexulti (brexpiprazole) reached \$1.1 billion [1]. This figure represents sales for the full year [1].
How is Rexulti Performing in the Market?
Rexulti's U.S. net sales for the fourth quarter of 2023 were \$283.2 million [1]. This indicates continued strong performance in the domestic market.
What is Rexulti Used For?
Rexulti is a medication approved for the treatment of schizophrenia in adults and as an adjunctive treatment for major depressive disorder in adults [2]. It is also approved for agitation associated with neurocognitive disorder due to Alzheimer's disease in adults [2].
When Does Rexulti's Patent Protection End?
Information regarding the specific expiration dates of Rexulti's patents and market exclusivity is available through patent tracking services [3]. Such services can provide details on upcoming patent cliffs and potential generic competition [3].
What Competitors Does Rexulti Face?
Rexulti competes in the markets for antipsychotics and adjunctive treatments for depression. Key competitors in these therapeutic areas include other atypical antipsychotics and antidepressant medications [4]. The competitive landscape is dynamic, with ongoing research and development of new treatments [4].
Are There Generic Alternatives to Rexulti?
Currently, generic versions of Rexulti are not available. The market exclusivity granted by patents and other regulatory protections prevents generic entry until these protections expire [3].
What Are the Potential Risks or Side Effects of Rexulti?
Like all medications, Rexulti carries potential risks and side effects. Common side effects can include akathisia, weight gain, and somnolence [2]. Serious risks include a boxed warning regarding increased mortality in elderly patients with dementia-related psychosis, and potential for tardive dyskinesia and neuroleptic malignant syndrome [2]. Patients should discuss these risks with their healthcare provider [2].
What Is the Regulatory Status of Rexulti?
Rexulti is approved by the U.S. Food and Drug Administration (FDA) for its indicated uses [2]. Regulatory approvals are based on extensive clinical trials demonstrating safety and efficacy [2].
---
Sources:
1. https://www.lundbeck.com/global/investors/financial-reports-and-presentations/quarterly-results
2. https://www.rexulti.com/
3. https://drugpatentwatch.com/
4. Internal Market Analysis